In 1777 NDMM patients treated on the Myeloma XI trial, patients with TP53 deletion showed features of advanced disease and associated morbidity, specifically poorer performance status (World Health Organization [WHO] performance status ≥2; P = 0.0012). The gene discussed is TP53; the disease is plasma cell myeloma.